The purpose of this study is to prove that luteal phase supplementation with recombinant LH can solve the luteal phase deficiency after Gnrh agonist oocytes triggering in women at risk of OHSS

开始日期2013-06-30

申办/合作机构-

EUCTR2010-022032-37-IT

/ Not yet recruitingN/A

Randomized, open-label, single centre study on ovarian stimulation in ART poor responders treated with recombinant FSH in association with recombinant LH.

开始日期2011-03-18

申办/合作机构

Casa di Cura Abano Terme Polispecialistica e Termale SpA

NCT01457703

/ CompletedN/AIIT

Reproductive Hormonal Alterations in Obesity, AIMS #1 & #2

The purpose of this study is to determine why obese women have lower hormone levels and less fertility than women of normal body weight. The proposal will examine the reproductive system at the level of the brain and the ovary to define the changes that happen leading to lowered hormone production. Women will be studied throughout a menstrual cycle and given medications that will test how well their pituitary gland can make hormones that stimulate the ovary (luteinizing hormone (LH) and follicle stimulating hormone (FSH)). They will also be given a medication to abolish estrogen production in the body and their response to this medication will be assessed. Finally, the ovary's ability to produce progesterone after ovulation will be examined.
--Hypotheses:
Obese women have reduced pituitary sensitivity to exogenous gonadotropin-releasing hormone (GnRH), but normal clearance of exogenous LH. (comparative study of obese compared to normal weight women)
Obese women have abnormally increased sensitivity to estradiol negative feedback which will be reversed by an aromatase inhibitor. (comparative study of obese compared to normal weight women)

开始日期2010-06-01

申办/合作机构

University of Colorado Denver

[+1]

100 项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的临床结果

登录后查看更多信息

100 项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的转化医学

登录后查看更多信息

100 项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的专利（医药）

登录后查看更多信息

116

项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的文献（医药）

2025-02-27·Endocrine Connections

Early adolescence assessment of eleven boys treated with continuous subcutaneous infusion of recombinant LH and FSH during infancy

Article

作者: Trabado, Severine ; Lecoeuvre, Adrien ; Rothenbuhler, Anya ; Linglart, Agnès ; Bouvattier, Claire ; Thomas-Teinturier, Cécile ; Lambert, Anne-Sophie ; Fouatih, Khadidja ; Bouligand, Jérôme ; Trouvin, Marie-Agathe

We previously observed that continuous subcutaneous gonadotropin infusion (CSGI) in infants with congenital hypogonadotropic hypogonadism (CHH) can mimic minipuberty.ObjectiveTo describe the early adolescence outcome of boys treated during the first year of life.MethodsIn this retrospective cohort study, we describe eleven boys with CHH aged 12 years (11.5–14.6) treated at the age of 4.5 months (2.0–11) with CSGI. As a retrospective control cohort, we report testicular function of 12 untreated boys with CHH aged 12 years (12–15.9).ResultsIn response to CSGI, serum testosterone and inhibin B levels increased from 0.03 ng/mL (0–0.07) to 2.25 ng/mL (1.12–3.86) and from 73 (11–173) to 401 (185–727) pg/mL, respectively. The testicular volume increased from 0.50 mL (0.5–1) to 1.50 mL (0.7–3). Orchidopexy was performed in 4/11 patients. Between end of CSGI and early adolescence period, testicular volume in the treated group decreased from 1.5 mL (0.7–3) to 1.05 mL (0.7–2.36) (P = 0.024) and differed from that in untreated boys (0.3 mL (0.13–1.3); reference range (mL) for the Tanner stage (0.5–4.7)). Concerning hormonal status, hormone levels were higher in the treated group than in untreated group: serum AMH and inhibin B levels in treated patients decreased from 1028 pmol/L (550–1750) and 356 (185–727) pg/mL at neonatal period to 331 pmol/L (85–479) and 68 pg/mL (19–239), respectively, at early adolescence and differed from those in untreated patients (57.5 (30–169) and 8 pg/mL (<5–37), respectively (P < 0.001)).ConclusionWe report the first long-term follow-up of boys with CHH treated with CSGI in infancy. Our results have shown that the CSGI treatment resulted in higher inhibin B, AMH levels and testicular volume, which had some persisting effects lasting until early adolescence age. Follow-up should be continued until the end of puberty to assess spermatogenesis.Significance statementMinipuberty is known to be of some importance for future fertility but is usually absent in infants with hypogonadotropic hypogonadism. CSGI treatment in minipuberty period can mimic this hormonal activation. We describe here the natural course at early adolescence of boys treated with CSGI during their first year of life. The effects shown in the study were higher inhibin B levels and larger testicular volume in patients treated by CSGI treatment, which had some persisting effects lasting until early adolescence period. Follow-up should be continued until the end of puberty to assess spermatogenesis in these patients.

2024-10-01·Human Reproduction

Undetected, natural conception pregnancies in luteal phase stimulations—case series and review of literature

Article

作者: Del Gallego, R ; Edades, J ; Kalafat, E ; Fatemi, H ; Ata, B ; Selim, S ; Lawrenz, B

AbstractSTUDY QUESTIONWhat is the risk of an undetected natural conception pregnancy during luteal phase ovarian stimulation, and how does it impact the pregnancy's course?SUMMARY ANSWERThe risk for an undetected, natural conception pregnancy in luteal phase ovarian stimulation is low and it appears that ovarian stimulation is unlikely to harm the pregnancy.WHAT IS KNOWN ALREADYRandom start ovarian stimulation appears to be similarly effective as early follicular stimulation start; and it allows ovarian stimulation to be started independent of the cycle day and throughout the cycle, in accordance with the patients’ and clinics’ schedule as long as there is no intention of a fresh embryo transfer in the same cycle. Starting ovarian stimulation in the luteal phase bears the possibility of an—at the timepoint of stimulation start—undetected, natural conception pregnancy that has already occurred. There is scarce data on the incidence of this event as well as on the possible implications of ovarian stimulation on the course of an existing pregnancy.STUDY DESIGN, SIZE, DURATIONThis retrospective observational study, performed between June 2017 and January 2024, analyzed luteal phase stimulations, in which a natural conception pregnancy was detected during the ovarian stimulation treatment for IVF/ICSI. Luteal phase stimulation was defined as ovarian stimulation started after ovulation and before the next expected menstrual bleeding, with a serum progesterone (P4) level of >1.5 ng/ml on the day of stimulation start or 1 day before.PARTICIPANTS/MATERIALS, SETTING, METHODSWomen who underwent a luteal phase ovarian stimulation in a tertiary referral ART center.MAIN RESULTS AND THE ROLE OF CHANCEA total of 488 luteal phase stimulation cycles were included in the analysis. Luteal phase stimulation was only started after a negative serum hCG measurement on the day or 1 day before commencement of ovarian stimulation. Ten patients (2.1%) had an undetected natural conception pregnancy at the time of luteal phase stimulation start. Eight of these patients underwent an ovarian stimulation in a GnRH-antagonist protocol and two in a progestin-primed stimulation protocol (PPOS). Recombinant FSH was used as stimulation medication for all patients, the patients with a PPOS protocol received additional recombinant LH. One pregnancy (0.2%) was detected after the oocyte retrieval, the other nine pregnancies were detected either due to persistent high serum progesterone levels or due to an increasing progesterone level after an initial decrease before oocyte retrieval. In the cycles with an undetected natural conception pregnancy, the median number of stimulation days was 8 days (range: 6–11 days) and median serum hCG at detection of pregnancy was 59 IU hCG (range: 14.91–183.1). From 10 patients with a pregnancy, three patients delivered a healthy baby, two patients had ongoing pregnancies at the time of summarizing the data, three patients had biochemical pregnancies (patient age: 30, 39, and 42 years), one patient had an ectopic pregnancy which required a salpingectomy, and one patient (age: 34 years) had an early pregnancy loss.LIMITATIONS, REASONS FOR CAUTIONThe retrospective study design and the small sample size can limit the accuracy of the estimates.WIDER IMPLICATIONS OF THE FINDINGSOverall, there is a small risk of undetected natural conception pregnancies when luteal phase stimulation is undertaken. It appears that there are no adverse effects through either direct effect on the embryo or indirectly through a detrimental effect on the corpus luteum function on the pregnancy in our cohort.STUDY FUNDING/COMPETING INTEREST(S)This study did not receive funding. The authors declare that there is no conflict of interest.TRIAL REGISTRATION NUMBERN/A.

2021-12-01·Reproductive BioMedicine Online3区 · 医学

Cumulus cell microRNA expression when LH is added to the ovarian stimulation protocol: a pilot study

3区 · 医学

Article

作者: Carvalho, Cristina V ; Bonetti, Tatiana C S ; Rodrigues, Fernanda ; Fraietta, Renato ; Motta, Eduardo L A ; Vigo, Francieli Maria

RESEARCH QUESTIONRecombinant FSH administration in ovarian stimulation for IVF is a standard procedure, whereas the role of LH is controversial. MicroRNAs (mRNA) are small endogenous non-coding transcripts that are involved in the regulation of many cellular processes, including foliculogenesis and gonadotrophin function. The aim was to study the possible role of miRNA in ovarian follicular development in groups having different ovarian stimulation protocols. Are there different miRNA expression profiles in cumulus cells of infertile women undergoing IVF? What are the regulated pathways?DESIGNThis prospective observational study included 13 patients who fulfilled the following inclusion criteria: younger than 38 years of age; a tubal infertility factor; a male factor; or idiopathic infertility. This is a pilot study in which the patients were aleatory enrolled into two groups: seven in FSH group (recombinant FSH, 225 IU) and six in FSH plus LH group (recombinant FSH, 150 IU + recombinant LH, 75 IU). The granulosa cells obtained from the follicular ovarian retrieval were analysed using polyerase chain reaction. Results were analysed using DIANA Tools, an online bioinformatics tool.RESULTSAmong the 84 microRNAs evaluated, 11 were differentially expressed between the groups, all of which were upregulated in the FSH plus LH group, compared with the FSH group. Differentially expressed miRNA profiles are related to oestrogen signalling, oocyte meiosis and pluripotent cells regulation.CONCLUSIONmiRNA overexpression in the FSH plus LH group is consistent with the independent and fundamental role of LH in folliculogenesis, leading to a distinct molecular response between groups.

100 项与 Recombinant LH(San Carlo Public Hospital, Potenza, Italy) 相关的药物交易

登录后查看更多信息

研发状态

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Bicetre Hospital (ESPE2022)	N/A	卡尔曼综合征	18	rhLH and rhFSH CSI	(淵壓鹽觸艱膚廠築襯顧) = 獵範網餘齋襯壓積窪餘衊遞鏇簾遞蓋積齋製遞 (願襯獵範鏇襯襯夢鹹膚 )	积极	2022-09-15
				recombinant LH	(淵壓鹽觸艱膚廠築襯顧) = 夢觸窪醖鹽鹽築糧繭鹽衊遞鏇簾遞蓋積齋製遞 (願襯獵範鏇襯襯夢鹹膚 )
NCT01457703 (CTgov)	N/A	肥胖	62	Recombinant LH+Cetrorelix+Letrozole+Gonadorelin-GnRH (BMI ≥30 kg/m2)	淵鹽鹹餘網膚繭艱網選(壓襯鑰鑰獵糧憲醖願鏇) = 範淵選膚鹽膚範鏇醖齋廠憲夢鹹膚衊鑰簾艱鑰 (簾築遞齋蓋淵襯構選構, 顧襯壓願簾醖糧窪範顧 ~ 網齋鏇艱窪遞積蓋憲築) 更多	-	2015-03-25
				Recombinant LH+Cetrorelix+Letrozole+Gonadorelin-GnRH (BMI 18-25 kg/m2)	淵鹽鹹餘網膚繭艱網選(壓襯鑰鑰獵糧憲醖願鏇) = 窪淵餘鏇觸襯窪積餘願廠憲夢鹹膚衊鑰簾艱鑰 (簾築遞齋蓋淵襯構選構, 鹽構衊繭淵糧顧鏇獵築 ~ 鏇簾網餘鏇鹽選顧選積) 更多